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Recent studies of calorie restriction in several organisms demonstrate an increase in mitochondrial 
activity that is associated with the salutary effects of this dietary restriction regimen. In this Essay, I 
speculate on how an increase in mitochondrial activity might provide benefit and discuss how diet, 
mitochondria, and sirtuins might interact in a pathway to slow aging and associated diseases.The earliest molecular theory of aging 
proposed that reactive oxygen species 
(ROS) damage macromolecules pro-
gressively over time, leading to a grad-
ual decline in cellular function (Harman, 
1956). ROS are produced as by-prod-
ucts of electron transport by the cells’ 
power plants for energy, mitochondria, 
during the generation of ATP by respi-
ration (Wallace, 2005). Thus, it has also 
been supposed that mitochondria play a 
uniquely important role in aging. Indeed, 
many constituents of mitochondria, such 
as the mitochondrial genome and com-
ponents of the electron transport chain, 
are damaged with aging, consistent with 
their proximity to the site of ROS produc-
tion. Furthermore, individuals with mito-
chondrial genetic diseases (Wallace, 
2005) or mice that generate frequent 
mutations in mitochondrial DNA (Kujoth 
et al., 2005; Trifunovic et al., 2004, 2005) 
display phenotypes that resemble pre-
mature aging.
By this reckoning, it was first sug-
gested that calorie restriction (CR), a 
dietary regimen that is known to extend 
life span in rodents and other organisms, 
exerts its salutary effects by slowing car-
bohydrate use, respiration, and the rate 
of damage produced by ROS. However, 
several recent findings have prompted a 
re-evaluation of this perhaps naive idea. 
First, a more careful examination of the 
physiology of CR has demonstrated 
that this regimen does not slow respi-
ration but in several examples actually 
upregulates mitochondrial function (see 
below). Second, CR appears to be a 
regulated rather than a passive process 
and requires regulatory proteins, such as the sirtuins, to exert its effects (Guar-
ente, 2006). This family of antiaging pro-
teins, related to the yeast SIR2 and its 
mammalian ortholog SIRT1, comprises 
NAD-dependent protein deacetylases 
(Imai et al., 2000; Landry et al., 2000) 
that increase life span in yeast, the worm 
Caenorhabditis elegans, and the fruit fly 
Drosophila. Three of the seven mamma-
lian sirtuins (SIRT3, 4, and 5) are targeted 
to mitochondria, and SIRT1 itself is a 
regulator of mitochondrial biogenesis 
(Guarente, 2006). Other regulatory pro-
teins involved in metabolism, such as the 
TOR and FOXO proteins (Kaeberlein et 
al., 2005a; Kenyon, 2005), may also play 
important roles in CR, but their connec-
tion to mitochondria is less clear.
These findings lead to a picture in 
which CR can exert a positive effect on 
mitochondria, boosting mitochondrial 
activity and hence providing at least 
some of the salutary effects of CR. In 
this Essay, I will review examples in 
which CR and sirtuins upregulate the 
activity of mitochondria in different 
organisms. Moreover, I will present 
several speculative models to explain 
how upregulation of mitochondrial bio-
genesis may confer antiaging effects 
on cells and organisms.
Mitochondria and CR-Induced 
Longevity
A regimen of moderate CR in yeast 
extends replicative life span of mother 
cells and increases respiration by 
funneling more pyruvate to the mito-
chondria for metabolism to CO2 at the 
expense of fermentation (Lin et al., 
2002) (see Figure 1). Importantly, block-Cell 13ing respiration by deleting the gene 
for cytochrome c1 prevents this CR-
driven extension in life span. Moreover, 
increasing respiration in yeast consti-
tutively through the enforced expres-
sion of the HAP4 transcriptional driver 
of mitochondrial biogenesis results in 
a long life span under normal caloric 
conditions that is not extended further 
by CR. The additional respiration dur-
ing CR increases the activity of yeast 
SIR2 and thereby extends life span.
In C. elegans, CR was recently 
shown to require two sensory neu-
rons, termed ASI neurons, in the head 
of the roundworm (Bishop and Guar-
ente, 2007). Signals emanating from 
these two cells trigger an increase in 
respiration, which, again, proved to 
be essential for CR-induced life span 
extension, as two different inhibitors of 
electron transport prevented this effect 
(see Figure 1). The response to CR in 
C. elegans requires two transcription 
factors, SKN-1 (Bishop and Guarente, 
2007) and PHA-4 (Panowski et al., 
2007), but so far sirtuins have not been 
implicated.
It appears that the degree and tim-
ing of energy limitation may influence 
the relationship between mitochon-
drial function and longevity. In yeast, a 
CR regimen using one tenth as much 
glucose as the moderate CR regimen, 
described above, was shown to extend 
yeast life span by a mechanism that did 
not require mitochondria or SIR2 (Kae-
berlein et al., 2005b). In C. elegans, an 
RNAi-imposed reduction in mitochon-
drial function during development sur-
prisingly extends life span, but in adult 2, January 25, 2008 ©2008 Elsevier Inc. 171
Figure 1. Calorie Restriction Pathways in Different Species
In yeast, SIR2 has been implicated downstream of mitochondrial changes in response to calorie restric-
tion (CR), whereas in mammals the SIR2 ortholog SIRT1 has been implicated upstream of mitochondrial 
changes. In C. elegans, sirtuins have not been implicated in dietary restriction to date. The pathway 
in mice shows that the increase in mitochondrial number and activity may work via the mitochondrial 
sirtuins SIRT3, 4, and 5 or by reducing reactive oxygen species (ROS). The drug Resveratrol and CR 
may increase SIRT1 activity, which is part of an autoregulatory feedback loop that includes the enzyme 
endothelial nitric oxide synthase (eNOS). worms such a reduction in mitochon-
drial function has no effect (Dillin et al., 
2002; Rea et al., 2007).
A priori, one cannot be certain 
which of the experimental conditions 
in the lower organisms is relevant to 
the standard CR protocol in mam-
mals (30%–40% reduction of ad libi-
tum feeding). However, recent findings 
have begun to link these mechanisms 
to mammalian CR. First, mice lacking 
SIRT1 are unable to mount the increase 
in foraging activity typical of this diet 
(Chen et al., 2005), suggesting a role 
of this sirtuin in the brain during CR. 
Moreover, transgenic mice that over-
express SIRT1 resemble CR mice in 
physiological parameters (decreased 
blood glucose, insulin, fat, and choles-
terol) and behavioral assays (improved 
rotarod performance and delayed mat-
ing) (Bordone et al., 2007).
Second, CR increases respiration as 
well as mitochondrial number per cell in 
mice (Nisoli et al., 2005) (see Figure 1). 
These increases require the endothe-
lial nitric oxide synthase (eNOS); nitric 
oxide is known to be capable of acti-
vating the SIRT1 promoter in cultured 
cells. These findings fit with the fact 172 Cell 132, January 25, 2008 ©2008 Elsethat the NAD/NADH ratio and SIRT1 
protein levels are increased in several 
rodent tissues during CR (Cohen et al., 
2004; Guarente, 2006). Interestingly, 
SIRT1 also deacetylates and activates 
the eNOS enzyme (Mattagajasingh 
et al., 2007), indicating that a positive 
feedback mechanism between SIRT1 
and eNOS may reset the levels of this 
sirtuin during CR.
Further molecular insight into the 
increase in mitochondrial function 
in CR is suggested by the relation-
ship between SIRT1 and PGC-1α, a 
transcriptional coactivator of nuclear 
genes encoding mitochondrial pro-
teins. SIRT1 was shown to deacetylate 
PGC-1α at several lysine residues and 
thereby increase its ability to transcrip-
tionally activate target genes (Rodgers 
et al., 2005; Gerhart-Hines et al., 2007). 
Thus, the increase in SIRT1 during CR 
should result in mitochondrial biogene-
sis in tissues such as muscle and white 
fat. Indeed, feeding mice the putative 
SIRT1 activator resveratrol upregu-
lates mitochondrial number in muscle 
(Lagouge et al., 2006). This compound 
also triggers numerous salutary effects 
to counteract a high caloric diet, includ-vier Inc.ing improved physical activity and lon-
ger average life span (Baur et al., 2006; 
Lagouge et al., 2006).
Finally, some of these effects found 
in mice also have been observed in a 
six month human trial in which subjects 
were calorie restricted to a degree that 
resulted in the expected reductions in 
body weight and blood insulin (Civi-
tarese et al., 2007). Most strikingly, 
muscle punch biopsies from these 
calorie-restricted individuals showed 
upregulation of SIRT1, eNOS, the mito-
chondrial protein TFAM, and mitochon-
drial number, compared to biopsies 
from control individuals on a normal 
diet (Figure 1). These findings suggest 
that a conserved pathway may oper-
ate in mammals during CR involving 
the activation of SIRT1 and eNOS that 
triggers an increase in mitochondrial 
activity.
Why Is Activation of Mitochondria 
Good?
Increased respiration in yeast and 
worms is required for CR-induced lon-
gevity, but the situation in mammals 
is only correlative. However, it is still 
worth considering possible mecha-
nisms to explain how salutary effects 
might be caused by or associated with 
the increase in number of mitochon-
dria, if only to spur new experiments. 
In yeast, Sir2p lies downstream of (that 
is, it responds to) increased respira-
tion in the CR longevity pathway (Fig-
ure 1). It has been suggested that this 
sirtuin is activated by the respiration-
triggered increase in the NAD/NADH 
ratio (Lin et al., 2004) and the induction 
of the PNC1 nicotinamidase (Ander-
son et al., 2003). In mammals on CR, 
it seems likely that sirtuins both trig-
ger (SIRT1) and respond to (SIRT3, 4, 
5) an increase in mitochondrial number 
and activity (Figure 1). I consider below 
five possible ways in which increased 
mitochondrial number and activity may 
be an integral part of a mechanism by 
which CR exerts antiaging effects in 
mammals.
A Mitochondrial Buffer to Aging
There is ample evidence that damage to 
mitochondria increases progressively 
with age (Wallace, 2005). This has been 
observed in the form of the accumula-
tion of mutations in mitochondrial DNA 
and a decline in the activity of mito-
chondrial enzymes and components 
of the electron transport chain. In the 
case of aging skeletal muscle syncitia, 
for example, zones of metabolically 
inactive tissue have been observed, 
due to expansion of mitochondria that 
become damaged during aging (Bua 
et al., 2006). A large body of evidence 
links mitochondrial dysfunction with 
diabetes (Lowell and Shulman, 2005), 
although a recent report surprisingly 
showed that deleting the apoptosis 
inducing factor AIF1 in muscle or liver 
reduced mitochondrial function and 
had salutary effects on metabolic dis-
ease (Pospisilik et al., 2007).
A higher pool of functional mitochon-
dria may ameliorate tissue damage sim-
ply by buffering cells (or the syncitia in 
muscle) against the gradual decline in the 
ability to produce energy as mitochon-
dria become damaged during aging. 
One may well wonder why mitochondrial 
number is not normally set to a higher 
level during ad libitum feeding to forestall 
this decline. It is important to remember 
that aging occurs postreproductively 
and is nonadaptive. Thus, under normal 
conditions, mitochondrial number and 
function will only fall sway to selective 
pressure until the reproductive period 
has been completed. During subsequent 
aging, there is minimal selective pres-
sure to maintain mitochondrial (or any 
other) robustness. By this logic, CR and 
perhaps other stressors may impose a 
new selective landscape in which robust 
somatic maintenance, rather than repro-
duction, is now at a premium and mito-
chondrial biogenesis favored.
Mitochondrial Regulation of Sirtuins
A second possibility is that the increase 
in mitochondrial function serves a regu-
latory function by changing the activity 
of regulatory proteins, exemplified by 
CR and Sir2p in yeast. Proteins capable 
of responding to metabolic changes in 
mitochondria that alter the NAD/NADH 
ratio include the three sirtuins located 
in that cellular compartment (SIRT3, 4, 
and 5). Both SIRT3 and SIRT4 have been 
shown to have important metabolic func-
tions in mitochondria (Guarente, 2006). 
Importantly, these two sirtuins were 
also recently shown to be involved in a 
stress-resistance pathway (Yang et al., 
2007). Cells that sustain DNA damage Figure 2. Mitochondrial Biogenesis and Reactive Oxygen Species
Shown is mitochondrial biogenesis during calorie restriction versus ad libitum feeding in mice and its pro-
posed effects on reactive oxygen species (ROS). In the ad libitum case, the number of electron transport 
chains is low, and if the rate of entry of electrons (red e−) exceeds the slowest step of flow through the 
chain, stalling of electrons at mitochondrial complexes I and III (blue e−) and production of ROS will be 
favored. During calorie restriction, mitochondrial biogenesis increases the number of electron transport 
chains, thereby reducing the rate of electron entry per electron transport chain. Calorie restriction may 
also increase the fraction of electrons that bypass complex I by entering the electron transport chain via 
the electron transfer flavoprotein dehydrogenase (ETF). These effects may reduce the production of ROS 
during calorie restriction and hence mitigate cellular damage, aging, and disease.will acutely deplete their nuclear NAD 
pool because of the activation of the 
NAD-cleaving enzyme poly-ADP-ribose 
polymerase (PARP), which is involved in 
DNA repair. However, the mitochondrial 
pool of NAD is preserved in part through 
the translocation of the NAD synthetic 
enzyme Nampt to mitochondria, where 
reinforced synthesis of NAD, SIRT3, and 
SIRT4 appears to be required to prevent 
apoptosis.
In the steady-state condition of CR, 
any changes in the NAD/NADH ratio 
due to altered metabolic activity in mito-
chondria are likely to equilibrate to the 
other cellular compartments by shuttle 
systems that operate across the mito-
chondrial membrane. Thus, the non-
mitochondrial sirtuins and indeed any 
other cellular proteins that bind to NAD 
may also be affected. In principle, it is 
also possible that changes in other small 
molecules due to altered mitochondrial 
activity may play important regulatory 
roles during CR.
Mitochondrial Regulation of ROS
ROS remain a likely cause of the decline 
in cellular and organismal vitality dur-
ing aging. There is good evidence that 
species that are long-lived produce Cell 132high levels of antioxidant enzymes and, 
moreover, that CR leads to a reduction in 
the production of ROS in a given organ-
ism (Weindruch and Walford, 1988). 
Furthermore, mice with a transgene 
targeting the antioxidant enzyme cata-
lase to the mitochondrial matrix have a 
longer life span (Schriner et al., 2005). 
Although ROS can be generated by a 
variety of enzymes of oxidative metab-
olism, the electron transport chain 
is their most significant source. How 
might the biogenesis of mitochondria, 
described above, relate to the reduction 
of ROS observed during CR? It was first 
assumed that ROS production by the 
electron transport chain would be pro-
portional to the respiration rate; how-
ever, recent evidence suggests that this 
view is too simplistic (Lopez-Lluch et al., 
2006). In fact, most ROS are produced 
by complexes I (NADH dehydrogenase) 
and III (cytochrome b-c1 complex) in 
the electron transport chain (Barja, 
2007; Pamplona and Barja, 2007), and 
this production actually appears to be 
enhanced by the stalling of electrons 
at these complexes (Kushnareva et al., 
2002; Barros et al., 2004) (see Figure 2). 
For example, ischemia will stall electron , January 25, 2008 ©2008 Elsevier Inc. 173
transport due to lack of a terminal elec-
tron acceptor and cause ROS produc-
tion upon oxygen reperfusion resulting 
in severe tissue damage.
Electron stalling occurs when the 
rate of entry of electrons into complex I 
of the electron transport chain exceeds 
their rate of transit through the slow-
est step of the chain. For example, if 
electron transit through complex IV 
were limiting, rapid entry of electrons 
into the electron transport chain could 
trigger electron stalling at complexes I 
and III (Figure 2). Ironically, the old idea 
that CR reduces carbohydrate use as 
fuel for the TCA cycle could explain a 
reduction in ROS production because 
NADH production and the rate of entry 
of electrons into the electron transport 
chain would be reduced. But this idea 
has been discredited because respira-
tion does not decrease during CR.
The biogenesis of mitochondria dur-
ing CR offers another possible explana-
tion. The increase in electron transport 
chain components should restrain ROS 
production because it will increase the 
number of entry points for electrons into 
the electron transport chain, thereby 
lowering the rate of entry into the chain 
and reducing the probability of electrons 
becoming stalled at complexes I and 
III (Figure 2). Further studies on mito-
chondrial bioenergetics should resolve 
whether such an effect is observed in 
tissues from animals on CR. The model 
discussed in this section does not 
require any additional regulatory com-
ponents to translate the upregulation of 
mitochondria into beneficial effects.
Mitochondrial Reprogramming to 
Fat Oxidation
CR changes the way in which different 
available energy sources in food are 
handled by the body. In caloric excess, 
carbohydrates are used for energy and 
fat is stored, presumably because it has 
a higher energy content per gram. How-
ever, during CR all energy sources are 
used, notably fat and amino acids, and 
the animal minimizes carbohydrate use in 
peripheral tissues to maintain adequate 
blood glucose levels for the brain (Wein-
druch and Walford, 1988). Therefore, in 
energy-producing tissues like muscle, 
there is a shift toward the β-oxidation of 
fatty acids to derive energy during CR, a 
process that occurs in mitochondria.174 Cell 132, January 25, 2008 ©2008 ElsevUnlike carbohydrate catabolism, 
in which most of the reducing power 
generated for electron transport is 
in the form of NADH, β-oxidation of 
fatty acids produces FADH at a molar 
equivalence of NADH. FADH must 
enter the electron transport chain not 
via complex I but via the electron trans-
fer flavoprotein dehydrogenase (ETF) 
(coupled to acyl-CoA dehydrogenase) 
(Figure 2). ETF passes electrons to 
ubiquinone, which then donates them 
to complex III and thence onward down 
the chain. Therefore, use of fat as an 
energy source increases the frequency 
with which electrons enter the electron 
transport chain by bypassing complex 
I. Given that complex I is one of the pri-
mary stations of ROS production, this 
simple metabolic shift from carbohy-
drate to fat utilization may reduce ROS 
production.
But what about the increase in mito-
chondrial biogenesis observed during 
CR? When electrons enter the elec-
tron transport chain at complex I, their 
transport results in the synthesis of 
three molecules of ATP by oxidative 
phosphorylation. However, when elec-
trons enter at ETF only two ATP mol-
ecules are made because the proton-
pumping complex I has been bypassed. 
Thus, it is possible that the observed 
mitochondrial biogenesis during CR 
compensates for the reduction in ATP 
production per reducing equivalent 
when fat is used as an energy source. 
This model would suggest that it is not 
an increase in respiration or even mito-
chondrial biogenesis per se that is ben-
eficial during CR but rather the partial 
bypass of complex I in the production 
of ATP. In this regard, it is interesting 
to note that the human CR trial did not 
record any increase in respiration but 
actually showed a decrease in whole 
body energy expenditure (Civitarese 
et al., 2007), even though there was an 
increase in mitochondrial  components.
As for model three, this idea is 
appealing for its simplicity but bears 
the caveat of placing great emphasis 
on the importance of ROS in aging. It 
is interesting to note that one of the 
most effective drugs for diabetes, met-
formin, can act as a partial inhibitor of 
complex I (Owen et al., 2000). Much 
of the benefit of this drug in treating ier Inc.metabolic disease has been attributed 
to the resulting activation of AMP-de-
pendent protein kinase (AMPK) (Zhou 
et al., 2001), which helps to reduce 
gluconeogenesis in liver and to drive 
the oxidation of fat in muscle. How-
ever, it is clearly possible that the inhi-
bition of complex I per se can help to 
reduce cellular damage and to foster 
long-term health benefits in metform-
in-treated individuals. The activation 
of AMPK may still serve an important 
regulatory role by inducing fatty-acid 
oxidation to ensure the maintenance 
of energy production.
Recycling of Damaged Mitochondria
Cells have the cytosolic ubiquitin/
proteasome system and mitochon-
drial proteases to degrade damaged 
or unwanted proteins and to replace 
them with newly synthesized ones 
(Varshavsky, 2005). Cells can also 
degrade damaged structures as large 
as organelles by a process called 
autophagy (Scherz-Shouval and Ela-
zar, 2007). This process transports 
damaged organelles, for example 
mitochondria, to lysosomes where 
they are degraded and their contents 
recycled. Obviously, if mitochon-
dria were degraded in this fashion, 
new synthesis would be required to 
maintain energy homeostasis. In this 
regard, it is possible that the increase 
in mitochondrial biogenesis induced 
by CR is a consequence of increased 
organelle turnover, and any increase 
in net mitochondrial synthesis is but a 
corollary. An increase in mitochondrial 
turnover might be beneficial for cells, 
given that they are among the most 
damaged structures during aging. It 
would not matter according to this 
model whether ROS or other agents 
generate the damage; the important 
outcome would be better maintenance 
of young mitochondria in aging cells. 
Consistent with this idea, autophagy 
has been reported to be required for 
the CR extension of life span in C. ele-
gans (Jia and Levine, 2007).
Importantly, a recent paper showed 
that SIRT1 deacetylates and activates 
several proteins of the autophagic 
machinery (Lee et al., 2007). Cells from 
SIRT1-deficient mice are defective in 
autophagy, and SIRT1-deficient mice 
have damaged organelles and dis-
play early postnatal lethality like mice 
defective in autophagy. Thus, the idea 
that salutary effects of CR spring from 
the activation of autophagy and the 
clearance of defective mitochondria is 
attractive.
However, several questions arise. 
First, can the autophagic machinery 
selectively recognize and destroy dam-
aged mitochondria? Second, does CR 
actually induce autophagy in mam-
mals? One might expect the answer 
to be yes, given that one consequence 
of autophagy is to provide a source of 
carbon and energy, and induction of 
autophagy during acute starvation is 
clearly observed. However, long-term 
CR is a steady-state process and does 
not impose the same degree of energy 
limitation as starvation, so whether 
it triggers autophagy is still an open 
question. In conclusion, the interesting 
possibility that autophagy of damaged 
mitochondria plays an important role in 
mammalian CR awaits further experi-
mentation.
Conclusion
Mitochondria have long been pro-
posed to play an important role in 
aging. Recent genetic findings in lower 
organisms have pinpointed sirtuins as 
antiaging genes, and at least four of 
the seven mammalian sirtuin homologs 
have mitochondria-associated func-
tions. CR is perhaps the most robust 
intervention that extends mammalian 
life span and has been associated with 
an increase in SIRT1 levels in several 
tissues and a corresponding increase 
in mitochondrial components. Here, I 
have presented several models for how 
this increase in mitochondria may have 
the effect of slowing aging and disease. 
Some of the models rely on an impor-
tant role of ROS in the aging process, 
whereas others do not. It is hoped 
that the next few years will see a fur-
ther convergence of genetic pathways 
with mitochondrial function, which will 
provide a comprehensive view of aging 
and antiaging mechanisms and will 
also explain how CR works. It seems 
likely that we are on the right track of 
acquiring this understanding, and that 
it will involve mechanisms rich in new 
and old ideas about aging and how to 
counteract it.ReFeReNCeS
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